Latest News
Latest News
HAVEN 2: Emicizumab represents new standard of care for hemophilia A with inhibitors
ATLANTA – Emicizumab safely prevents or substantially reduces bleeds in children with hemophilia A with inhibitors.
Conference Coverage
Polymerization inhibitor improves hemoglobin levels in adolescents with SCD
ATLANTA – Voxelotor demonstrated consistent, sustained improvements in hemoglobin levels in adolescents with sickle cell disease in a phase 2b...
Latest News
Sickle cell: Customized stem cells may improve transfusion efficacy, safety
ATLANTA – Matching red cell products to sickle-cell disease patients with rare Rh antibodies can be done with a little fancy stem cell footwork...
Conference Coverage
VIDEO: Novel PARP inhibitor boosts PFS in HER2– breast cancer with BRCA mutations
Conference Coverage
DNA vaccine + PD-1 blockade shows promise in mCRPC
NATIONAL HARBOR, MD. – Combining PD-1 pathway inhibition with a DNA vaccine led to antitumor changes in mCRPC patients in a randomized clinical...
Conference Coverage
VIDEO: Weight loss cut risk of breast cancer
SAN ANTONIO – Women in the Women’s Health Initiative Observational Study who lost at least 5% of their body weight had a significant 12% reduction...
From the Journals
Tc-325 effective for immediate GI tumor bleeding
This powder seems to be more predictably effective in providing initial hemostasis in upper GI tumor bleeding, compared with conventional methods...
Conference Coverage
Adjuvant trastuzumab for 1 year remains standard of care for early HER2+ breast cancer
SAN ANTONIO – The phase 3 SOLD trial failed to show a 9 week course of trastuzumab as noninferior to the standard 12-month course.
From the Journals
Poststroke depression raises risk of cerebrovascular death 35-fold
Depression after a stroke is deadly and should be monitored and treated.
Conference Coverage
2 = 5 for additional AI therapy for postmenopausal HR+ breast cancer
SAN ANTONIO - Five years of additional therapy with anastrozole was no more effective than 2 additional years.
Conference Coverage
Shaping practice: Z1071 continues to redefine axillary management
SAN DIEGO – The Z1071 landmark study proves the safety of leaving the axilla intact in node-positive patients who respond well to neoadjuvant...